SK Hynix Announces ₩40 Trillion Share Buyback, Samsung Biologics & Voronoi Accelerate New Drug Development

The market is particularly noting the delayed cancer recurrence effect observed in combination therapy with the immuno-oncology drug Keytruda.

This amounts to about ₩40 trillion, and the company is expected to intensify its buying efforts if the stock price declines.

This is interpreted as a reflection of the company's robust business foundation and market demand.

Such large-scale orders are expected to be a crucial driving force for Samsung Biologics' quantum leap.

Samsung Biologics has officially entered the European market by acquiring a Swiss peptide company. Through this, sales are expected to begin in Europe from the third quarter. The company is also expanding its global sales network by opening a sales office in Amsterdam, Netherlands.

The company is actively entering the obesity treatment market, aiming for portfolio diversification. This strategy is intended to secure growth engines for its bio-pharmaceutical CDMO business and enhance its competitiveness in the global market.

Voronoi's non-small cell lung cancer treatment VRN 11 recorded high objective response rates in clinical trials. It is gaining attention particularly for its effect in overcoming Tagrisso resistance (C797S mutation). The treatment has also shown effectiveness in treating brain metastasis due to its high blood-brain barrier (BBB) permeability.

Currently, VRN 11 has completed global clinical approvals in regions including North America and Asia. Voronoi anticipates a license-out (L/O) for VRN 11 in the second half of this year, increasing expectations for revenue generation through technology transfer.

The VRN 11 clinical trial included not only patients who had never received cancer treatment but also C797S mutation patients who had failed treatment with Tagrisso. The high treatment efficacy observed across this broad patient spectrum will be used as strong data to prove technical superiority in global technology negotiations.

This is expected to maximize royalty and milestone payments in future license-out (L/O) agreements. Successful clinical results in diverse patient groups are considered a key factor in boosting VRN 11's market potential.

This alignment between preclinical and clinical data enhances the predictability of new drug development and serves as a positive signal for future clinical success.

This is interpreted as reflecting the market's high expectations for the government's key policy drive.

Haein's case, showing high returns in a short period, suggests to investors the importance of discovering new policy beneficiary stocks.